A study used deep learning to analyze MRI scans of 14,748 cognitively normal participants, aged 23–90 years; 354 participants with mild cognitive impairment, aged 55–92 years; and 529 participants with Alzheimer’s disease, aged 55–96 years.

Lindsay A. Farrer, PhD, chief of biomedical genetics at Boston University Chobanian & Avedisian School of Medicine, has been selected as the recipient of a 3-year, $450,000 Zenith Fellows Award from the Alzheimer’s Association for his project, “Genes to AD Therapy: A Roadmap for Personalized Medicine.” Zenith Fellows Awards are among the most prestigious in Alzheimer's research worldwide.

A $1.5M grant has been awarded to William Van Nostrand, co-executive director of the University of Rhode Island’s George & Anne Ryan Institute for Neuroscience and professor of pharmaceutical and biomedical sciences in the URI College of Pharmacy, to study cerebral amyloid angiopathy (CAA), a disease prevalent in the elderly population and commonly found in patients with Alzheimer's disease.

New South Australian research will seek to uncover how the brain’s defense systems identify and remove damaged proteins, paving the way for new approaches to preventing and treating dementia.

A University of Minnesota research team has identified a type of plaque that represents a new potential therapeutic target for Alzheimer’s disease. The findings were recently published in Nature Neuroscience.

- Professor Byung Chang Suh’s team becomes the first in the world to uncover the mechanism that regulates “calcium channels,” which are essential for neural signal transmission - Presents a key milestone for developing new therapeutics for intractable brain disorders, including Alzheimer's disease, autism spectrum disorder, and epilepsy - Published in the Proceedings of the National Academy of Sciences, a world-renowned scientific journal